New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. We drink water every day. Several times a day, ideally. But ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...

ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...

The Bank Secrecy Act (BSA) is one of several federal statutes that establish prohibitions and requirements related to anti-money laundering (AML) enforcement. It is also one of several federal ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

Worried about what's in your tap water? A high-performing reverse osmosis (RO) countertop system is one of the best ways to protect your family. Unlike basic filters, these advanced systems are ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. The ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. Financial institution (FI) fraud and anti-money laundering ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help ...